Cargando…

Systemic Review and Meta-Analysis of the Clinical Efficacy and Adverse Effects of Zhengqing Fengtongning Combined with Methotrexate in Rheumatoid Arthritis

Chinese medicines are gaining wider acceptance. They have been used for treating rheumatoid arthritis (RA) for thousands of years, and the need to investigate the interaction between Chinese medicines and western medicines is widely recognized. In this study, a large number of RCTs and CCTs were ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiu-min, Huang, Run-yue, Huang, Qing-chun, Chu, Yong-liang, Yan, Jing-yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561327/
https://www.ncbi.nlm.nih.gov/pubmed/26379753
http://dx.doi.org/10.1155/2015/910376
_version_ 1782389016094572544
author Chen, Xiu-min
Huang, Run-yue
Huang, Qing-chun
Chu, Yong-liang
Yan, Jing-yao
author_facet Chen, Xiu-min
Huang, Run-yue
Huang, Qing-chun
Chu, Yong-liang
Yan, Jing-yao
author_sort Chen, Xiu-min
collection PubMed
description Chinese medicines are gaining wider acceptance. They have been used for treating rheumatoid arthritis (RA) for thousands of years, and the need to investigate the interaction between Chinese medicines and western medicines is widely recognized. In this study, a large number of RCTs and CCTs were analyzed to systematically assess the effects and adverse events of Zhengqing Fengtongning (ZQFTN) for RA. Eleven studies that contained 956 participants (508 in the treatment group; 448 in the control group) were included. The results showed that although ZQFTN combined with methotrexate MTX could not decrease the swollen joint count and tender joint count of RA patients better than MTX alone, the combination therapy might relieve the duration of morning stiffness (SMD: −16.06; 95% CI: −28.77 to −3.34), reduce laboratory indexes (RF: SMD: −10.84; 95% CI: −19.39 to −2.29; ESR: SMD: −7.26; 95% CI: −11.54 to −2.99; CRP: SMD: −3.66; 95% CI: −5.94 to −1.38), and improve the overall effect (RR: 1.08; CI: 1.01 to 1.16) better than monotherapy. The combination therapy was significantly better in controlling adverse drug reactions (RR: 0.60; 95% CI: 0.46 to 0.79). Through this systematic review, we found that ZQFTN combined with MTX for the treatment of RA might have better clinical efficacy than MTX only and might be superior in terms of controlling adverse drug reactions.
format Online
Article
Text
id pubmed-4561327
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-45613272015-09-14 Systemic Review and Meta-Analysis of the Clinical Efficacy and Adverse Effects of Zhengqing Fengtongning Combined with Methotrexate in Rheumatoid Arthritis Chen, Xiu-min Huang, Run-yue Huang, Qing-chun Chu, Yong-liang Yan, Jing-yao Evid Based Complement Alternat Med Review Article Chinese medicines are gaining wider acceptance. They have been used for treating rheumatoid arthritis (RA) for thousands of years, and the need to investigate the interaction between Chinese medicines and western medicines is widely recognized. In this study, a large number of RCTs and CCTs were analyzed to systematically assess the effects and adverse events of Zhengqing Fengtongning (ZQFTN) for RA. Eleven studies that contained 956 participants (508 in the treatment group; 448 in the control group) were included. The results showed that although ZQFTN combined with methotrexate MTX could not decrease the swollen joint count and tender joint count of RA patients better than MTX alone, the combination therapy might relieve the duration of morning stiffness (SMD: −16.06; 95% CI: −28.77 to −3.34), reduce laboratory indexes (RF: SMD: −10.84; 95% CI: −19.39 to −2.29; ESR: SMD: −7.26; 95% CI: −11.54 to −2.99; CRP: SMD: −3.66; 95% CI: −5.94 to −1.38), and improve the overall effect (RR: 1.08; CI: 1.01 to 1.16) better than monotherapy. The combination therapy was significantly better in controlling adverse drug reactions (RR: 0.60; 95% CI: 0.46 to 0.79). Through this systematic review, we found that ZQFTN combined with MTX for the treatment of RA might have better clinical efficacy than MTX only and might be superior in terms of controlling adverse drug reactions. Hindawi Publishing Corporation 2015 2015-08-24 /pmc/articles/PMC4561327/ /pubmed/26379753 http://dx.doi.org/10.1155/2015/910376 Text en Copyright © 2015 Xiu-min Chen et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Chen, Xiu-min
Huang, Run-yue
Huang, Qing-chun
Chu, Yong-liang
Yan, Jing-yao
Systemic Review and Meta-Analysis of the Clinical Efficacy and Adverse Effects of Zhengqing Fengtongning Combined with Methotrexate in Rheumatoid Arthritis
title Systemic Review and Meta-Analysis of the Clinical Efficacy and Adverse Effects of Zhengqing Fengtongning Combined with Methotrexate in Rheumatoid Arthritis
title_full Systemic Review and Meta-Analysis of the Clinical Efficacy and Adverse Effects of Zhengqing Fengtongning Combined with Methotrexate in Rheumatoid Arthritis
title_fullStr Systemic Review and Meta-Analysis of the Clinical Efficacy and Adverse Effects of Zhengqing Fengtongning Combined with Methotrexate in Rheumatoid Arthritis
title_full_unstemmed Systemic Review and Meta-Analysis of the Clinical Efficacy and Adverse Effects of Zhengqing Fengtongning Combined with Methotrexate in Rheumatoid Arthritis
title_short Systemic Review and Meta-Analysis of the Clinical Efficacy and Adverse Effects of Zhengqing Fengtongning Combined with Methotrexate in Rheumatoid Arthritis
title_sort systemic review and meta-analysis of the clinical efficacy and adverse effects of zhengqing fengtongning combined with methotrexate in rheumatoid arthritis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561327/
https://www.ncbi.nlm.nih.gov/pubmed/26379753
http://dx.doi.org/10.1155/2015/910376
work_keys_str_mv AT chenxiumin systemicreviewandmetaanalysisoftheclinicalefficacyandadverseeffectsofzhengqingfengtongningcombinedwithmethotrexateinrheumatoidarthritis
AT huangrunyue systemicreviewandmetaanalysisoftheclinicalefficacyandadverseeffectsofzhengqingfengtongningcombinedwithmethotrexateinrheumatoidarthritis
AT huangqingchun systemicreviewandmetaanalysisoftheclinicalefficacyandadverseeffectsofzhengqingfengtongningcombinedwithmethotrexateinrheumatoidarthritis
AT chuyongliang systemicreviewandmetaanalysisoftheclinicalefficacyandadverseeffectsofzhengqingfengtongningcombinedwithmethotrexateinrheumatoidarthritis
AT yanjingyao systemicreviewandmetaanalysisoftheclinicalefficacyandadverseeffectsofzhengqingfengtongningcombinedwithmethotrexateinrheumatoidarthritis